Alzamend Neuro (Alzamend Neuro) EV-to-EBIT : -0.38 (As of May. 04, 2024)

Alzamend Neuro EV-to-EBIT Chart

Alzamend Neuro Quarterly Data
	Apr19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EV-to-EBIT	Get a 7-Day Free Trial													-3.67	-3.22	-2.75	-0.73	-0.44

Competitive Comparison of Alzamend Neuro's EV-to-EBIT

For the Biotechnology subindustry, Alzamend Neuro's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alzamend Neuro's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzamend Neuro's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alzamend Neuro's EV-to-EBIT falls into.

Alzamend Neuro EV-to-EBIT Calculation

Alzamend Neuro's EV-to-EBIT for today is calculated as:

Alzamend Neuro's current Enterprise Value is $4.70 Mil.
Alzamend Neuro's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzamend Neuro  (NAS:ALZN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Alzamend Neuro's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

Alzamend Neuro's Enterprise Value for the quarter that ended in Jan. 2024 was $5.41 Mil.
Alzamend Neuro's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzamend Neuro EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Alzamend Neuro (Alzamend Neuro) Business Description